Explore the words cloud of the TransBioLine project. It provides you a very rough idea of what is the project "TransBioLine" about.
The following table provides information about the project.
|Coordinator Country||Switzerland [CH]|
|Total cost||27˙906˙491 €|
|EC max contribution||13˙999˙997 € (50%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-02-01 to 2024-01-31|
Take a look of project's partnership.
|1||UNIVERSITAT ZURICH||CH (ZURICH)||coordinator||2˙424˙271.00|
|2||SIGNATOPE GMBH||DE (REUTLINGEN)||participant||1˙990˙000.00|
|3||CHARITE - UNIVERSITAETSMEDIZIN BERLIN||DE (BERLIN)||participant||1˙386˙193.00|
|4||ABX CRO ADVANCED PHARMACEUTICAL SERVICES FORSCHUNGSGESELLSCHAFT MBH||DE (DRESDEN)||participant||1˙294˙360.00|
|5||TAMIRNA GMBH||AT (WIEN)||participant||1˙231˙000.00|
|6||THE UNIVERSITY OF LIVERPOOL||UK (LIVERPOOL)||participant||940˙250.00|
|7||SYNAPSE RESEARCH MANAGEMENT PARTNERS SL||ES (MADRID)||participant||900˙000.00|
|8||THE UNIVERSITY OF NOTTINGHAM||UK (NOTTINGHAM)||participant||832˙700.00|
|9||INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA||LU (Esch-sur-Alzette)||participant||624˙125.00|
|10||MLM MEDICAL LABS GMBH||DE (MONCHENGLADBACH)||participant||604˙800.00|
|11||LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN||DE (MUENCHEN)||participant||443˙450.00|
|12||METAHEPS GMBH||DE (PLANEGG)||participant||284˙000.00|
|13||UNIVERSIDAD DE MALAGA||ES (MALAGA)||participant||246˙452.00|
|14||SERVICIO ANDALUZ DE SALUD||ES (SEVILLA)||participant||188˙946.00|
|15||FUNDACIO PRIVADA INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU||ES (BARCELONA)||participant||182˙600.00|
|16||UNIVERSITY OF NEWCASTLE UPON TYNE||UK (NEWCASTLE UPON TYNE)||participant||109˙475.00|
|17||LANDSPITALI UNIVERSITY HOSPITAL||IS (REYKJAVIK)||participant||87˙325.00|
|18||ASSISTANCE PUBLIQUE HOPITAUX DE PARIS||FR (PARIS)||participant||81˙400.00|
|19||UNIVERSITEIT LEIDEN||NL (LEIDEN)||participant||79˙150.00|
|20||UNIVERSIDAD DE SALAMANCA||ES (SALAMANCA)||participant||69˙500.00|
|21||Eli Lilly and Company Limited||UK (Basingstoke)||participant||0.00|
|22||F. HOFFMANN-LA ROCHE AG||CH (BASEL)||participant||0.00|
|23||JANSSEN PHARMACEUTICA NV||BE (BEERSE)||participant||0.00|
|24||MERCK SHARP & DOHME CORP||US (WHITEHOUSE STATION NJ)||participant||0.00|
|25||NOVARTIS PHARMA AG||CH (BASEL)||participant||0.00|
|26||PFIZER LIMITED||UK (SANDWICH)||participant||0.00|
|27||SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT||FR (Chilly Mazarin)||participant||0.00|
Qualified biomarkers help to optimize drug development and patient safety, yet for the regulatory acceptance of safety biomarkers substantial sample sizes are needed to ensure adequate case and control numbers, and robust evidence sufficient for qualification. To address this challenge, a consortium of leading European research institutions and SMEs has been established. The consortium will generate exploratory and confirmatory data enabling regulatory qualification of new safety biomarkers for application in drug development; establish robust datasets on the DILI, DIKI, DIPI, DIVI and DINI biomarkers to enhance diagnosis of disease; develop and validate assays for new safety biomarkers; implement profiles of circulating miRNAs as tissue and mechanism specific diagnostic tool; have key safety biomarkers accepted as qualified drug development tools by EMA, FDA, and PMDA. Given the significant expertise available across the consortium, the group will be able to tackle the key challenges related to successful biomarker qualification. A key driving principle of the consortium is cross-linking via existing networks of top profile research institutions, as well as capitalizing on existing data and resources. The Consortium is embedded into a network of international research collaborations such as the Pro-Euro-DILI-registry, TransQST, eTRANSAFE, the i2b2 tranSMART Foundation, the CIOMS DILI working group, EPoS, LITMUS, and BBMRI. To optimize regulatory interaction, we intend to continue our successful collaboration with non-European consortia such as PSTC, the FNIH Biomarkers Consortium, and US DILIN. A key expected result of the consortium will be a “Safety Biomarker Factory”, regularly qualifying new markers, with an associated “Safety Biomarker Warehouse”, providing to the scientific community, industry, and patients detailed data and information, and knowledge across a large spectrum of advanced safety biomarkers.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRANSBIOLINE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TRANSBIOLINE" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
Bringing a prophylactic Ebola vaccine to licensureRead More
NOVEL GRAM-NEGATIVE ANTIBIOTIC NOWRead More